Scotiabank Issues Positive Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target upped by Scotiabank from $53.00 to $75.00 in a research report report published on Monday,Benzinga reports. They currently have a sector outperform rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on AGIO. Raymond James reaffirmed an “outperform” rating and set a $51.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Leerink Partners downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $56.00.

Agios Pharmaceuticals Stock Down 21.1 %

Shares of Agios Pharmaceuticals stock opened at $48.64 on Monday. The stock’s 50-day simple moving average is $50.01 and its 200-day simple moving average is $46.57. The company has a market capitalization of $2.77 billion, a price-to-earnings ratio of 4.28 and a beta of 0.80. Agios Pharmaceuticals has a 52 week low of $20.96 and a 52 week high of $62.58.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at $988,346.74. The trade was a 11.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.93% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Large investors have recently made changes to their positions in the company. Northcape Wealth Management LLC purchased a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth about $244,000. Bank of New York Mellon Corp increased its holdings in Agios Pharmaceuticals by 13.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 223,151 shares of the biopharmaceutical company’s stock worth $9,622,000 after acquiring an additional 27,193 shares in the last quarter. Panagora Asset Management Inc. acquired a new position in Agios Pharmaceuticals during the second quarter worth $7,540,000. TD Asset Management Inc lifted its holdings in Agios Pharmaceuticals by 34.6% during the second quarter. TD Asset Management Inc now owns 210,472 shares of the biopharmaceutical company’s stock valued at $9,076,000 after purchasing an additional 54,054 shares in the last quarter. Finally, North Star Asset Management Inc. purchased a new stake in shares of Agios Pharmaceuticals during the second quarter worth about $216,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.